Journal article
TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT
N Lalaoui, A Morlé, D Mérino, G Jacquemin, E Iessi, A Morizot, S Shirley, B Robert, E Solary, C Garrido, O Micheau
Plos One | Published : 2011
Abstract
Background: TRAIL/Apo2L is a pro-apoptotic ligand of the TNF family that engages the apoptotic machinery through two pro-apoptotic receptors, TRAIL-R1 and TRAIL-R2. This cell death program is tightly controlled by two antagonistic receptors, TRAIL-R3 and TRAIL-R4, both devoid of a functional death domain, an intracellular region of the receptor, required for the recruitment and the activation of initiator caspases. Upon TRAIL-binding, TRAIL-R4 forms a heteromeric complex with the agonistic receptor TRAIL-R2 leading to reduced caspase-8 activation and apoptosis. Methodology/Principal Findings: We provide evidence that TRAIL-R4 can also exhibit, in a ligand independent manner, signaling proper..
View full abstractGrants
Awarded by Agence Nationale de la Recherche
Awarded by Agence Nationale de la Recherche (ANR)
Funding Acknowledgements
This work is supported by grants of the Conseil Regional de Bourgogne, the INCa (Institut National du Cancer) Canceropole Grand-Est, (Agence Nationale de la Recherche, ANR-06-JCJC-0103 and 07-PCV-0031) and the European Community (ApopTrain Marie Curie RTN). NL, A. Morizot, DM, A. Morle and GJ are supported by fellowships from the Ligue Nationale contre le Cancer, the Ministry of Research and Education, the ARC (Association pour la Recherche sur le Cancer), the INSERM and the Conseil Regional de Bourgogne. EI was supported by a fellowship from the Apoptrain Marie Curie RTN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.